GlassScriptPhysician profile
John M Orr
NPI 1700442464
$6,708.24
in general payments reported to CMS, 2019-2025
17 companies · $4,571 in 2025
The $4,571 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $414 · 2024: $1,723 · 2025: $4,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,234 · Consulting Fee: $2,200 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,234.35 |
| Consulting Fee | $2,200.00 |
| Education | $273.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,452.63 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $745.08 | 2023-2025 | |
| Abbvie INC. | $610.05 | 2023-2025 | |
| Galderma Laboratories, L.P. | $326.91 | 2024-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $325.97 | 2023-2025 | |
| Lilly USA, LLC | $233.11 | 2023-2025 | Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $185.32 | 2025 | Dupixent |
| Dermavant Sciences, INC. | $156.76 | 2024 | Vtama |
| Revance Therapeutics, INC. | $154.70 | 2024-2025 | Daxxify |
| Incyte Corporation | $149.86 | 2024-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $130.55 | 2023-2025 | Ilumya |
| Leo Pharma INC. | $113.24 | 2024 | Adbry |
| Arcutis Biotherapeutics, INC. | $48.32 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $22.04 | 2025 | Sotyktu |
| Ucb, INC. | $18.73 | 2023 | Cimzia |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $17.76 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $17.21 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.